Cargando…

First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery

ABSTRACT: Main protease (Mpro) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) intervenes in the replication and transcription processes of the virus. Hence, it is a lucrative target for anti-viral drug development. In this study, molecular modeling analyses were performed on the str...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Sk. Abdul, Banerjee, Suvankar, Singh, Samayaditya, Qureshi, Insaf Ahmed, Gayen, Shovanlal, Jha, Tarun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782049/
https://www.ncbi.nlm.nih.gov/pubmed/33400085
http://dx.doi.org/10.1007/s11030-020-10166-3
_version_ 1783631810766307328
author Amin, Sk. Abdul
Banerjee, Suvankar
Singh, Samayaditya
Qureshi, Insaf Ahmed
Gayen, Shovanlal
Jha, Tarun
author_facet Amin, Sk. Abdul
Banerjee, Suvankar
Singh, Samayaditya
Qureshi, Insaf Ahmed
Gayen, Shovanlal
Jha, Tarun
author_sort Amin, Sk. Abdul
collection PubMed
description ABSTRACT: Main protease (Mpro) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) intervenes in the replication and transcription processes of the virus. Hence, it is a lucrative target for anti-viral drug development. In this study, molecular modeling analyses were performed on the structure activity data of recently reported diverse SARS-CoV-2 Mpro inhibitors to understand the structural requirements for higher inhibitory activity. The classification-based quantitative structure–activity relationship (QSAR) models were generated between SARS-CoV-2 Mpro inhibitory activities and different descriptors. Identification of structural fingerprints to increase or decrease in the inhibitory activity was mapped for possible inclusion/exclusion of these fingerprints in the lead optimization process. Challenges in ADME properties of protease inhibitors were also discussed to overcome the problems of oral bioavailability. Further, depending on the modeling results, we have proposed novel as well as potent SARS-CoV-2 Mpro inhibitors. GRAPHIC ABSTRACT: [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11030-020-10166-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7782049
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77820492021-01-05 First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery Amin, Sk. Abdul Banerjee, Suvankar Singh, Samayaditya Qureshi, Insaf Ahmed Gayen, Shovanlal Jha, Tarun Mol Divers Original Article ABSTRACT: Main protease (Mpro) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) intervenes in the replication and transcription processes of the virus. Hence, it is a lucrative target for anti-viral drug development. In this study, molecular modeling analyses were performed on the structure activity data of recently reported diverse SARS-CoV-2 Mpro inhibitors to understand the structural requirements for higher inhibitory activity. The classification-based quantitative structure–activity relationship (QSAR) models were generated between SARS-CoV-2 Mpro inhibitory activities and different descriptors. Identification of structural fingerprints to increase or decrease in the inhibitory activity was mapped for possible inclusion/exclusion of these fingerprints in the lead optimization process. Challenges in ADME properties of protease inhibitors were also discussed to overcome the problems of oral bioavailability. Further, depending on the modeling results, we have proposed novel as well as potent SARS-CoV-2 Mpro inhibitors. GRAPHIC ABSTRACT: [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11030-020-10166-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2021-01-05 2021 /pmc/articles/PMC7782049/ /pubmed/33400085 http://dx.doi.org/10.1007/s11030-020-10166-3 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Amin, Sk. Abdul
Banerjee, Suvankar
Singh, Samayaditya
Qureshi, Insaf Ahmed
Gayen, Shovanlal
Jha, Tarun
First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
title First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
title_full First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
title_fullStr First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
title_full_unstemmed First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
title_short First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
title_sort first structure–activity relationship analysis of sars-cov-2 virus main protease (mpro) inhibitors: an endeavor on covid-19 drug discovery
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782049/
https://www.ncbi.nlm.nih.gov/pubmed/33400085
http://dx.doi.org/10.1007/s11030-020-10166-3
work_keys_str_mv AT aminskabdul firststructureactivityrelationshipanalysisofsarscov2virusmainproteasemproinhibitorsanendeavoroncovid19drugdiscovery
AT banerjeesuvankar firststructureactivityrelationshipanalysisofsarscov2virusmainproteasemproinhibitorsanendeavoroncovid19drugdiscovery
AT singhsamayaditya firststructureactivityrelationshipanalysisofsarscov2virusmainproteasemproinhibitorsanendeavoroncovid19drugdiscovery
AT qureshiinsafahmed firststructureactivityrelationshipanalysisofsarscov2virusmainproteasemproinhibitorsanendeavoroncovid19drugdiscovery
AT gayenshovanlal firststructureactivityrelationshipanalysisofsarscov2virusmainproteasemproinhibitorsanendeavoroncovid19drugdiscovery
AT jhatarun firststructureactivityrelationshipanalysisofsarscov2virusmainproteasemproinhibitorsanendeavoroncovid19drugdiscovery